4.7 Article

Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 26, Pages 3176-+

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2013.50.4662

Keywords

-

Categories

Funding

  1. Melanoma Institute Australia

Ask authors/readers for more resources

A 52-year-old man has unresectable locally recurrent melanoma of the left foot (Fig 1) and pulmonary metastases. Nine months before this presentation, he underwent a wide local excision and sentinel node biopsy for an acral melanoma on his left heel. Pathology disclosed Breslow thickness of 4.8 mm, Clark level IV, and tumor ulceration with a mitotic rate of 37 mitoses/mm(2). Both sentinel nodes in the left groin were positive for melanoma cells, which expressed S100, HMB45, and melan A. At subsequent left inguinal dissection, seven more nodes showed no additional nodal metastases. Within 3 months of his original surgery, the patient developed a local recurrence in the foot, and over the subsequent 6 months, he underwent serial local excisions and topical diphencyprone treatment. A recent staging scan showed at least 20 foci of in-transit disease in the left lower leg and foot, as well as a solitary lung metastasis (12 mm). His Eastern Cooperative Oncology Group performance status is 1, with no significant comorbidities. High-resolution melt followed by sequencing of an in-transit metastasis showed there is no BRAF exon 15 mutation. However, Sanger sequencing of KIT exons 9, 11, 13, and 17, performed as screening for a clinical trial enrolling patients with metastatic acral and mucosal melanomas, showed an exon 13 K642E mutation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Alison M. Weppler, Laetitia Da Meda, Ines Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina Long, Serigne N. Lo, Ina Nordman, Christopher B. Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Celeste Lebbe, Shahneen Sandhu

Summary: The response to immune checkpoint inhibitors (ICIs) in metastatic Merkel cell carcinoma (mMCC) is not durable off treatment, but retreatment shows promising results.

EUROPEAN JOURNAL OF CANCER (2023)

Article Dermatology

IFN-y Signaling Sensitizes Melanoma Cells to BH3 Mimetics

Zizhen Ming, Su Yin Lim, Ashleigh Stewart, Bernadette Pedersen, Elena Shklovskaya, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Jenny H. Lee, Richard A. Scolyer, Georgina V. Long, Helen Rizos

Summary: Immunotherapy targeting PD-1 and/or CTLA4 can lead to durable responses in some melanoma patients. However, treatment resistance and lack of response are common. This study identifies a vulnerability in melanoma driven by immune cell activity, providing potential strategies for combination therapies.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Pathology

Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets

Ismael A. Vergara, Karina Aivazian, Matteo S. Carlino, Alexander D. Guminski, Nigel G. Maher, Kerwin F. Shannon, Sydney Ch'ng, Robyn P. M. Saw, Georgina Long, James S. Wilmott, Richard A. Scolyer

Summary: Basal cell carcinomas (BCCs) are the most common malignant tumors in humans and are usually easily managed by surgery or topical therapies. However, metastatic BCCs are rare and may have distinct biological characteristics. Through genomic profiling, aberrant activation of Hedgehog signaling and alterations in multiple signaling pathways were identified in metastatic BCCs. The presence of clonal origin in matched local recurrences and metastases suggests that molecular profiling can assist in determining the nature and origin of poorly differentiated metastatic tumors. Dysregulation of the Hippo and PI3K/AKT pathways were implicated in the metastatic progression of BCCs, making them potential therapeutic targets.

MODERN PATHOLOGY (2023)

Article Oncology

Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Hansol Lee, Angela L. Ferguson, Camelia Quek, Ismael A. Vergara, Ines Pires daSilva, Ruth Allen, Tuba Nur Gide, Jordan W. Conway, Lambros T. Koufariotis, Nicholas K. Hayward, Nicola Waddell, Matteo S. Carlino, Alexander M. Menzies, Robyn P. M. Saw, Elena Shklovskaya, Helen Rizos, Serigne Lo, Richard A. Scolyer, Georgina V. Long, Umaimaintha Palendira, James S. Wilmott

Summary: This study characterized intratumoral macrophage populations in melanoma biopsies and investigated the association between CD16-expressing macrophage densities and treatment outcomes for patients receiving anti-PD-1 monotherapy or a combination with anti-CTLA-4. The results showed that patients who responded to combination therapy had higher CD16 macrophage densities compared to those who did not respond. Additionally, patients with high intratumoral densities of CD16 macrophages had a significantly longer progression-free survival. These findings suggest that CD16 macrophages may serve as a potential biomarker for response to combination immunotherapies in metastatic melanoma patients.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma

Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Barouyr Baroudjian, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Turkan Ozturk Topcu, Florentia Dimitriou, Andrew Haydon, Serigne N. Lo, Alexander M. Menzies, Georgina Long

Summary: This study investigates the efficacy of a combination therapy strategy involving low-dose ipilimumab (IPI) and an anti-PD1 antibody in advanced melanoma. The results show that the majority of patients who progress following low-dose IPI and subsequently receive IPI 3 mg/kg (IPI3) have a positive response to this treatment. This suggests that the dosage of IPI is critical for certain patients.

EUROPEAN JOURNAL OF CANCER (2023)

Article Immunology

Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy

Jake R. Thompson, Julia Lai-Kwon, Rachael L. Morton, Alexander D. Guminski, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu, Michael P. Brown, Alexander M. Menzies, Grant A. McArthur, Serigne N. Lo, Georgina Long, Iris Bartula

Summary: This study investigated the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients undergoing ipilimumab-nivolumab or nivolumab treatment for 18 weeks. The results showed that there was no significant deterioration in HRQoL for MBM patients treated with either ipilimumab-nivolumab or nivolumab within the first 18 weeks of treatment initiation.

IMMUNOTHERAPY (2023)

Review Oncology

Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now

Georgina V. Long, Alexander M. Menzies, Richard A. Scolyer

Summary: The role of neoadjuvant therapy is shifting in oncology, from reducing surgical morbidity to a life-saving treatment with curative promise. Recent studies suggest that checkpoint inhibitors administered in the neoadjuvant setting may have greater clinical efficacy compared to the adjuvant setting.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

Talal El Zarif, Amin H. Nassar, Elio Adib, Bailey G. Fitzgerald, Jiaming Huang, Tarek H. Mouhieddine, Paul G. Rubinstein, Taylor Nonato, Rana R. McKay, Mingjia Li, Arjun Mittra, Dwight H. Owen, Robert A. Baiocchi, Michael Lorentsen, Christopher Dittus, Nazli Dizman, Adewunmi Falohun, Noha Abdel-Wahab, Adi Diab, Anand Bankapur, Alexandra Reed, Chul Kim, Aakriti Arora, Neil J. Shah, Edward El-Am, Elie Kozaily, Wassim Abdallah, Ahmad Al-Hader, Batool Abu Ghazal, Anwaar Saeed, Claire Drolen, Melissa G. Lechner, Alexandra Drakaki, Javier Baena, Caroline A. Nebhan, Tarek Haykal, Michael A. Morse, Alessio Cortellini, David J. Pinato, Alessia Dalla Pria, Evan Hall, Veli Bakalov, Nathan Bahary, Aarthi Rajkumar, Ankit Mangla, Vishal Shah, Parminder Singh, Frank Aboubakar Nana, Nerea Lopetegui-Lia, Danai Dima, Ryan W. Dobbs, Pauline Funchain, Rabia Saleem, Rachel Woodford, Georgina V. Long, Alexander M. Menzies, Carlo Genova, Giulia Barletta, Sonam Puri, Vaia Florou, Dame Idossa, Maristella Saponara, Paola Queirolo, Giuseppe Lamberti, Alfredo Addeo, Melissa Bersanelli, Dory Freeman, Wanling Xie, Erin G. Reid, Elizabeth Y. Chiao, Elad Sharon, Douglas B. Johnson, Ramya Ramaswami, Mark Bower, Brinda Emu, Thomas U. Marron, Toni K. Choueiri, Lindsey R. Baden, Kathryn Lurain, Guru P. Sonpavde, Abdul Rafeh Naqash

Summary: Compared with people living without HIV, people living with HIV and cancer have been excluded from immune checkpoint inhibitor trials. There is also a lack of real-world data on the use of ICIs in this population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Clinical Neurology

Case series: Immune checkpoint inhibitor-induced transverse myelitis

Sophie Chatterton, Shuo Xi, Jessica Xi Jia, Martin Krause, Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Suran L. Fernando, Therese Boyle, Samuel Kwok, Andrew Duggins, Deme Karikios, John D. E. Parratt

Summary: Four cases of ICI-induced transverse myelitis were reported in Australia. All patients had clinical evidence of inflammation in the cerebrospinal fluid and longitudinally extensive transverse myelitis on MRI spine. Prompt intensive immunomodulation is favored to reduce morbidity and mortality, and there is a risk of relapse after cessation of immunomodulatory therapy.

FRONTIERS IN NEUROLOGY (2023)

Article Oncology

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

Benjamin C. C. Park, Sathya Narayanan, Alexander Gavraldis, Fei Ye, Run Fan, Ryan J. J. Sullivan, Genevieve Boland, Kerry L. Reynolds, Justin M. M. Balko, Matteo S. S. Carlino, Georgina V. V. Long, Leyre Zubiri, Alexander M. M. Menzies, Douglas B. B. Johnson

Summary: Immune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). The characterization of rare immune related adverse events (RirAEs) is limited, making accurate diagnosis and management difficult.

ONCOIMMUNOLOGY (2023)

Article Oncology

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

Prachi Bhave, Angela Hong, Serigne N. Lo, Rebecca Johnson, Johanna Mangana, Douglas B. Johnson, Ozgecan Dulgar, Zeynep Eroglu, Hui-Ling Yeoh, Andrew Haydon, Georg C. Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kaehler, Axel Hausschild, Grant A. McArthur, Alexander Maxwell Menzies, Georgina Long, Wei Wang, Matteo S. Carlino

Summary: This study investigates the role of adjuvant radiation therapy (RT) in patients with melanoma who experience locoregional disease recurrence during or after adjuvant anti-PD-1-based immunotherapy. The results show that adjuvant RT is associated with improved locoregional disease control, but does not affect the risk of distant recurrence.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

COLUMBUS-AD: phase III study of adjuvant encorafenib plus binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

Alexander C. J. van Akkooi, Axel Hauschild, Georgina Long, Mario Mandala, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul C. Lorigan, Alexander M. M. Eggermont

Summary: Stage IIB/IIC melanoma has a high risk of recurrence, but adjuvant therapies such as anti-PD-1 antibodies and BRAF MEK inhibitor therapy show promise in improving survival. The ongoing COLUMBUS-AD trial investigates the effectiveness of a BRAF-MEK inhibitor combination therapy in patients with BRAF-mutated IIB/IIC melanoma.

FUTURE ONCOLOGY (2023)

Article Oncology

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fabio Franke, Tudor E. Ciuleanu, Caio Pereira, Eva Munoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbe, Gaelle Quereux, Friedegund Meier, Brendan D. Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A. Tagliaferri, Nikhil I. Khushalani

Summary: Despite the efficacy of Bempegaldesleukin (BEMPEG) in the treatment of melanoma, the PIVOT IO 001 study did not meet its primary end points, with increased toxicity observed with the combination of BEMPEG plus NIVO.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3+anti-PD-1-based immunotherapies

Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer

Summary: This study evaluated the association between LAG-3 expression and clinical outcomes in metastatic melanoma patients treated with anti-LAG-3 and anti-PD-1 immunotherapy. The results showed that LAG-3 expression was related to treatment response and tumor-infiltrating lymphocytes, and patients with ≥ 1% LAG-3+ cells had longer progression-free survival.

ONCOIMMUNOLOGY (2023)

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

No Data Available